Whitehawk Therapeutics, Inc. (WHWK)

AI-Powered SEC Filing Analysis

Insider Trading Filed: 2026-04-10

Key Insights

  • The CEO, David James Lennon, sold 14,500 shares of Whitehawk Therapeutics, Inc. (WHWK) at $3.38 per share, potentially indicating some near-term selling pressure on the stock.
  • Lennon continues to hold a significant stake of 518,622 shares in the company, suggesting he maintains a positive long-term outlook.
  • The sale appears to be a routine transaction to cover tax withholding obligations related to the vesting of restricted stock units, rather than a broader change in the CEO's investment position.
Filing tone (AI): Neutral
View Original Filing →

Filings on this page are at least 90 days old. In the app, any new Whitehawk Therapeutics, Inc. filing is analysed the moment you open it.

Download on theApp Store Get it onGoogle Play

Important Information

AI-generated analysis is for informational purposes only. Always read original SEC filings and consult with qualified professionals before making investment decisions.